Price
Target price
-
-
-
-
-
-
WKN: 893882 / Symbol: GNTLF / Name: Genetic / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Genetic Technologies Ltd. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Genetic Technologies Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genetic Technologies Ltd. | - | - | - | - | - | - | - |
| Invion Ltd | 0.000% | 0.000% | -2.439% | -63.636% | -50.000% | 300.000% | 150.000% |
| TALI Digital Ltd. | - | 0.000% | 20.000% | 5900.000% | -11.765% | 5900.000% | 140.000% |
| Immutep LTD ADR | -5.630% | -9.884% | -18.421% | -81.098% | -88.077% | -83.684% | -92.289% |
News
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
Key Points
- Interested in Black Diamond Therapeutics, Inc.? Here are five stocks we like better.
- Silevertinib showed encouraging Phase 2 lung cancer data, including a 60% objective response
Pelthos Therapeutics Q1 Earnings Call Highlights
Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch